BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598. [PMID: 1584260 DOI: 10.1056/nejm199206113262403] [Cited by in Crossref: 1411] [Cited by in F6Publishing: 338] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Rusch VW. Five decades of progress in surgical oncology: Tumors of the lung and esophagus. J Surg Oncol 2022;126:921-5. [PMID: 36087084 DOI: 10.1002/jso.27033] [Reference Citation Analysis]
2 Ren LH, Zhu Y, Chen R, Shrestha Sachin M, Lu Q, Xie WH, Lu T, Wei XY, Shi RH. Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma. World J Gastrointest Oncol 2022; 14(9): 1758-1770 [DOI: 10.4251/wjgo.v14.i9.1758] [Reference Citation Analysis]
3 Sridharan S, Day F, Loh J, Lynam J, Smart J, Holt B, Mandaliya H, Bonaventura A, Kumar M, Martin J. Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer. Radiat Oncol 2022;17. [DOI: 10.1186/s13014-022-02127-x] [Reference Citation Analysis]
4 De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, Vernerey D. Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer? Cancers (Basel) 2022;14:4043. [PMID: 36011035 DOI: 10.3390/cancers14164043] [Reference Citation Analysis]
5 Boustani J, Créhange G. [Dose-escalated radiotherapy in esophageal cancer: A review of the literature]. Cancer Radiother 2022:S1278-3218(22)00127-5. [PMID: 36008261 DOI: 10.1016/j.canrad.2022.06.021] [Reference Citation Analysis]
6 Zheng YH, Zhao EH. Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction. World J Gastroenterol 2022; 28(31): 4299-4309 [DOI: 10.3748/wjg.v28.i31.4299] [Reference Citation Analysis]
7 Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol 2022:S0923-7534(22)03793-0. [PMID: 35963482 DOI: 10.1016/j.annonc.2022.08.001] [Reference Citation Analysis]
8 Quéro L, Besnard C, Guillerm S, Hennequin C. Actualités en radiothérapie digestive : le cancer de l’œsophage. Cancer/Radiothérapie 2022. [DOI: 10.1016/j.canrad.2022.06.004] [Reference Citation Analysis]
9 Chen X, Zhang S, Liu J, Ren M, Xing D, Qin H. Controlling dielectric loss of biodegradable black phosphorus nanosheets by iron-ion-modification for imaging-guided microwave thermoacoustic therapy. Biomaterials 2022;287:121662. [DOI: 10.1016/j.biomaterials.2022.121662] [Reference Citation Analysis]
10 Sakin A, Ozcelik M, Sahin S, Aydemir O, Aldemir MN, Iliklerden UH, Kotan MC. The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy. Surgical Oncology 2022;43:101809. [DOI: 10.1016/j.suronc.2022.101809] [Reference Citation Analysis]
11 Chen T, Xu B, Chen H, Sun Y, Song J, Sun X, Zhang X, Hua W. Transcription factor NFE2L3 promotes the proliferation of esophageal squamous cell carcinoma cells and causes radiotherapy resistance by regulating IL-6. Computer Methods and Programs in Biomedicine 2022. [DOI: 10.1016/j.cmpb.2022.107102] [Reference Citation Analysis]
12 Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang Q, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh C, Mummudi N, Joshi A, Ferri L, Wong RK, O’callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong F, Chao Y, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol 2022;12:917961. [DOI: 10.3389/fonc.2022.917961] [Reference Citation Analysis]
13 Hingorani DV, Allevato MM, Camargo MF, Lesperance J, Quraishi MA, Aguilera J, Franiak-pietryga I, Scanderbeg DJ, Wang Z, Molinolo AA, Alvarado D, Sharabi AB, Bui JD, Cohen EEW, Adams SR, Silvio Gutkind J, Advani SJ. Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-31601-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.07.003] [Reference Citation Analysis]
15 Gong J, Zhang W, Huang W, Liao Y, Yin Y, Shi M, Qin W, Zhao L. CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study. Radiother Oncol 2022:S0167-8140(22)04171-8. [PMID: 35750106 DOI: 10.1016/j.radonc.2022.06.010] [Reference Citation Analysis]
16 Nakajo K, Yoda Y, Yamashita H, Takashima K, Murano T, Kadota T, Shinmura K, Ikematsu H, Akimoto T, Yano T. Salvage endoscopic resection for cT1N0M0 local recurrence after chemoradiotherapy for esophageal squamous cell carcinoma: endoscopic submucosal dissection versus endoscopic mucosal resection. Jpn J Clin Oncol 2022:hyac090. [PMID: 35675653 DOI: 10.1093/jjco/hyac090] [Reference Citation Analysis]
17 Shin KE. Epidural abscess formation after chemoradiation therapy for esophageal cancer: A case report and literature review. Medicine (Baltimore) 2022;101:e29426. [PMID: 35623076 DOI: 10.1097/MD.0000000000029426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. European Urology 2022. [DOI: 10.1016/j.eururo.2022.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Qi Z, Pei P, Zhang Y, Chen H, Yang S, Liu T, Zhang Y, Yang K. 131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer. J Control Release 2022;346:240-9. [PMID: 35469982 DOI: 10.1016/j.jconrel.2022.04.029] [Reference Citation Analysis]
20 Schiffner C, Christiansen H, Brandes I, Grannas G, Wichmann J, Merten R. Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits? Strahlenther Onkol 2022. [PMID: 35416495 DOI: 10.1007/s00066-022-01929-y] [Reference Citation Analysis]
21 Bandhate K, Diwan A. Palliative radiotherapy and quality of life in patients with locally advanced thoracic esophageal cancer: a single centre experience from Central India. Rep Pract Oncol Radiother 2022;27:104-12. [PMID: 35402038 DOI: 10.5603/RPOR.a2021.0136] [Reference Citation Analysis]
22 Bridges S, Thomas B, Radhakrishna G, Hawkins M, Holborow A, Hurt C, Mukherjee S, Nixon L, Crosby T, Gwynne S. SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.03.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Schweizer C, Fietkau R, Putz F. [Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer]. Strahlenther Onkol 2022. [PMID: 35286400 DOI: 10.1007/s00066-022-01921-6] [Reference Citation Analysis]
24 Viegas C, Pereira DSM, Fonte P. Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment. Materials 2022;15:2086. [DOI: 10.3390/ma15062086] [Reference Citation Analysis]
25 Zhu H, Lu X, Jiang J, Lu J, Sun X, Zuo Y. Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma. Dose-Response 2022;20:155932582210767. [DOI: 10.1177/15593258221076720] [Reference Citation Analysis]
26 Chou WC, Lai CC, Hung CY, Hsueh SW, Yeh KY, Lu CH, Tsang NM, Chang PH, Ho YW, Chen SY, Lin YC, Hung YS. Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy. Cancer Control 2022;29:10732748211045276. [PMID: 34994207 DOI: 10.1177/10732748211045276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kraszkiewicz M, Napieralska A, Wydmański J, Suwiński R, Majewski W. Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer. Technol Cancer Res Treat 2022;21:15330338221086085. [PMID: 35296187 DOI: 10.1177/15330338221086085] [Reference Citation Analysis]
28 Ji Y, Du X, Chen M. Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer-Reply. JAMA Oncol 2021. [PMID: 34967851 DOI: 10.1001/jamaoncol.2021.6843] [Reference Citation Analysis]
29 Joseph DM, Malik MI, Jonnadula J, Ahmed F, Valiyaveettil D. Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study. South Asian J Cancer 2021;10:151-4. [PMID: 34938676 DOI: 10.1055/s-0041-1727067] [Reference Citation Analysis]
30 Créhange G, Modesto A, Vendrely V, Quéro L, Mirabel X, Rétif P, Huguet F. Radiotherapy for cancers of the oesophagus, cardia and stomach. Cancer Radiother 2021:S1278-3218(21)00312-7. [PMID: 34955417 DOI: 10.1016/j.canrad.2021.11.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sugimura K, Miyata H, Tanaka K, Makino T, Takeno A, Shiraishi O, Motoori M, Yamasaki M, Kimura Y, Hirao M, Fujitani K, Yasuda T, Mori M, Eguchi H, Yano M, Doki Y. Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results. Ann Surg 2021;274:e465-72. [PMID: 33065643 DOI: 10.1097/SLA.0000000000004564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Sun D, Chen Q, Gai Z, Zhang F, Yang X, Hu W, Chen C, Yang G, Hörmann S, Kullak-Ublick GA, Visentin M. The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin. Front Pharmacol 2021;12:684545. [PMID: 34603016 DOI: 10.3389/fphar.2021.684545] [Reference Citation Analysis]
33 Holyoake DLP, Smyth EC. Chemoradiotherapy or Surgery for Very Early Esophageal Squamous Cancer: Can a Nonrandomized Trial Give Us the Answer? Gastroenterology 2021;161:1793-5. [PMID: 34536450 DOI: 10.1053/j.gastro.2021.09.023] [Reference Citation Analysis]
34 Xin N, Wei R, Huang K, Chen Z, Liu C, Fang Y, Xu Z, Ding X, Tang H. Comparative study on short-term efficacy of single incision plus one (SI+1) port and multiportal 3D laparoscopic minimally invasive esophagectomy. J Gastrointest Oncol 2021;12:1277-84. [PMID: 34532087 DOI: 10.21037/jgo-21-441] [Reference Citation Analysis]
35 Rogers MP, DeSantis AJ, DuCoin CG. Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. Cancers (Basel) 2021;13:4352. [PMID: 34503162 DOI: 10.3390/cancers13174352] [Reference Citation Analysis]
36 Imai T, Tanaka Y, Sato Y, Mase J, Suetsugu T, Fukada M, Yasufuku I, Iwata Y, Mori R, Imai H, Kato T, Okumura N, Matsuhashi N, Takahashi T, Futamura M, Yoshida K. The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis. Indian J Surg Oncol 2021;:1-9. [PMID: 34483594 DOI: 10.1007/s13193-021-01419-0] [Reference Citation Analysis]
37 Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, Xu G, Bu S, Song B, Xie K, Huang S, Zheng Y, Sheng L, Lai X, Chen Y, Cheng L, Hu X, Ji W, Fang M, Kong Y, Yu X, Li H, Li R, Shi L, Shen W, Zhu C, Lv J, Huang R, He H, Chen M. Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol 2021. [PMID: 34351356 DOI: 10.1001/jamaoncol.2021.2705] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Vlacich G, Ballard A, Badiyan SN, Spraker M, Henke L, Kim H, Lockhart AC, Park H, Suresh R, Huang Y, Robinson CG, Bradley JD, Samson PP. A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. Clin Transl Radiat Oncol 2021;30:19-25. [PMID: 34278011 DOI: 10.1016/j.ctro.2021.06.007] [Reference Citation Analysis]
39 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Xiao Z. Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Front Oncol 2021;11:618776. [PMID: 34235073 DOI: 10.3389/fonc.2021.618776] [Reference Citation Analysis]
40 Chang X, Deng W, Wang X, Zhou Z, Yang J, Guo W, Liu M, Qi X, Li L, Zhang K, Zhang M, Shi Y, Liu K, Zhao Y, Wang H, Yu Z, Zhang J, Wang L, Qiao X, Han C, Zhu S, Zhang R, Chen J, Hu C, Zhang F, Hou X, Pang Q, Zhang W, Li G, Lin H, Sun X, Ge X, Li C, Ge H, Li D, Wang Y, Lu N, Gao X, Qin S, Tian Y, Xiao Z. Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. Radiat Oncol 2021;16:102. [PMID: 34107984 DOI: 10.1186/s13014-020-01691-4] [Reference Citation Analysis]
41 Wang L, Wang X, Ren X, Han C, Xiao Z, Zhu S, Qiao X, Zhou Z, Shen W, Chen J, Pang Q, Zhang W, Zhao Y, Wang X, Sun X, Ge X, Zhang K, Hu M, Li G, Liu M, Wang Y. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A). Transl Cancer Res 2021;10:2932-43. [PMID: 35116602 DOI: 10.21037/tcr-21-505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Xu L, Chen J, Guo H, Huang R, Guo L, Yu Y 2nd, Zhai T, Wu F, Chen Z, Li D, Chen C. Distribution of Peripheral Blood Cells in Esophageal Cancer Patients During Concurrent Chemoradiotherapy Predicts Long-Term Locoregional Progression Hazard After Treatment (GASTO1072). Cancer Manag Res 2021;13:4203-15. [PMID: 34079373 DOI: 10.2147/CMAR.S307695] [Reference Citation Analysis]
43 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Gao L, Wang S, Xiao Z. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. Thorac Cancer 2021;12:1831-40. [PMID: 33949784 DOI: 10.1111/1759-7714.13971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Li C, Wang X, Wang L, Chen J, Zhang W, Pang Q, Zhao Y, Sun X, Zhang K, Li G, Li L, Qiao X, Liu M, Wang Y, Deng L, Wang W, Bi N, Zhang T, Deng W, Ni W, Chang X, Han W, Zhou Z, Liang J, Feng Q, Wang L, Chen D, Lv J, Zhu S, Han C, Xiao Z. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncol 2021;60:627-34. [PMID: 33793382 DOI: 10.1080/0284186X.2021.1902564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
46 Pöttgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH, Lax H, Stuschke M. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Radiat Oncol 2021;16:59. [PMID: 33757534 DOI: 10.1186/s13014-021-01788-4] [Reference Citation Analysis]
47 Ino A, Sakanaka K, Inoo H, Ishida Y, Kanda J, Mizowaki T. Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation. Int Cancer Conf J 2021;10:201-6. [PMID: 34221832 DOI: 10.1007/s13691-021-00479-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yeom JG, Kim JH, Kim JW, Cho Y, Lee IJ, Lee CG, Chun J, Youn YH, Park H. Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:1255. [PMID: 33809157 DOI: 10.3390/cancers13061255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
50 Guo J, Zhang S, Li H, Hassan MOO, Lu T, Zhao J, Zhang L. Lung Metastases in Newly Diagnosed Esophageal Cancer: A Population-Based Study. Front Oncol 2021;11:603953. [PMID: 33718154 DOI: 10.3389/fonc.2021.603953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ikebuchi Y, Yoshida A, Kurumi H, Kamitani Y, Yasui S, Nakada Y, Kawaguchi K, Yashima K, Isomoto H. Salvage Photodynamic Therapy Using Talaporfin Sodium for Local Failure of Esophageal Squamous Cell Carcinoma. Yonago Acta Med 2021;64:120-5. [PMID: 33642911 DOI: 10.33160/yam.2021.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yang X, Wang L, Du H, Lin B, Yi J, Wen X, Geng L, Du X. Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. Medicine (Baltimore) 2021;100:e24328. [PMID: 33546064 DOI: 10.1097/MD.0000000000024328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143-53. [PMID: 33533655 DOI: 10.2217/fon-2020-0969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wang WP, Ma J, Lu Q, Han Y, Li XF, Jiang T, Zhao JB. Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma. Turk J Gastroenterol 2020;31:948-54. [PMID: 33626010 DOI: 10.5152/tjg.2020.19757] [Reference Citation Analysis]
57 Derby S, Forshaw M, Lowrie C, Grose D, Marashi H, McLoone P, Wilson C, McIntosh D. Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus. BMJ Open Gastroenterol 2021;8:e000492. [PMID: 33504498 DOI: 10.1136/bmjgast-2020-000492] [Reference Citation Analysis]
58 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
59 Yang X, Zhai Y, Bi N, Zhang T, Deng L, Wang W, Wang X, Chen D, Zhou Z, Wang L, Liang J. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. Chin J Cancer Res 2021;33:53-60. [PMID: 33707928 DOI: 10.21147/j.issn.1000-9604.2021.01.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wu Z, Zeng F, Zhang L, Zhao S, Wu L, Qin H, Xing D. Defect-rich titanium nitride nanoparticle with high microwave-acoustic conversion efficiency for thermoacoustic imaging-guided deep tumor therapy. Nano Res 2021;14:2717-27. [DOI: 10.1007/s12274-020-3277-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Mishra S, Ahmad F, Singh S, Singh RK, Das KJM, Kumar S. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. Cancer Rep (Hoboken) 2021;4:e1332. [PMID: 33369258 DOI: 10.1002/cnr2.1332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H, Sato Y, Motoyama S, Hashimoto M. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers (Basel) 2020;13:E8. [PMID: 33375169 DOI: 10.3390/cancers13010008] [Reference Citation Analysis]
63 Nayan N, Bhattacharyya M, Jagtap VK, Kalita AK, Sunku R, Roy PS. Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study. South Asian J Cancer 2018;7:27-30. [PMID: 29600230 DOI: 10.4103/sajc.sajc_178_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
64 Dermine S, Lévi-Strauss T, Abou Ali E, Belle A, Leblanc S, Bibault JE, Barré A, Palmieri LJ, Brezault C, Dhooge M, Terris B, Dohan A, Soyer P, Berger A, Rahmi G, Coriat R, Chaussade S, Barret M. Organ Preservation after Endoscopic Resection of Early Esophageal Cancer with a High Risk of Lymph Node Involvement. Cancers (Basel) 2020;12:E3598. [PMID: 33276430 DOI: 10.3390/cancers12123598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M, Nagata Y. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res 2021;62:142-8. [PMID: 33392619 DOI: 10.1093/jrr/rraa110] [Reference Citation Analysis]
66 Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Baba S, Sugimura H, Murai J, Pommier Y, Furuta T. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer 2020;20:1123. [PMID: 33218331 DOI: 10.1186/s12885-020-07574-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Walter F, Jell C, Zollner B, Andrae C, Gerum S, Ilhan H, Belka C, Niyazi M, Roeder F. [F18] FDG-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful? Strahlenther Onkol 2021;197:780-90. [PMID: 33104815 DOI: 10.1007/s00066-020-01701-0] [Reference Citation Analysis]
68 Luo H, Jiang W, Ma L, Chen P, Fang M, Ding L, Hua Y, Du D, Jing Z, Xie R, Song Y, Wang J, Zhou R, Tian Z, Wu S. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial. JAMA Netw Open 2020;3:e2019440. [PMID: 33026449 DOI: 10.1001/jamanetworkopen.2020.19440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, Deng L, Wang W, Liu W, Liang J, Zhang T, Bi N, Wang J, Zhai Y, Feng Q, Lv J, Li L, Xiao Z. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer 2020;20:901. [PMID: 32962674 DOI: 10.1186/s12885-020-07387-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Chang X, Deng L, Ni W, Li C, Han W, Gao LR, Wang S, Zhou Z, Chen D, Feng Q, Liang J, Bi N, Lv J, Gao S, Mao Y, Xue Q, Xiao Z. Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer 2020;20:877. [PMID: 32928136 DOI: 10.1186/s12885-020-07315-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Lu Z, Wang Z, Li D. Application of atomic force microscope in diagnosis of single cancer cells. Biomicrofluidics 2020;14:051501. [PMID: 32922587 DOI: 10.1063/5.0021592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Chen Z, Yao N, Zhang S, Song Y, Shao Q, Gu H, Ma J, Chen B, Zhao H, Tian Y. Identification of critical radioresistance genes in esophageal squamous cell carcinoma by whole-exome sequencing. Ann Transl Med 2020;8:998. [PMID: 32953798 DOI: 10.21037/atm-20-5196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 DeCesaris CM, Berger M, Choi JI, Carr SR, Burrows WM, Regine WF, Simone CB 2nd, Molitoris JK. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointest Oncol 2020;11:663-73. [PMID: 32953150 DOI: 10.21037/jgo-20-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, Bogers JHA, Braam PM, Muijs CKT, de Jong MA, Kasperts N, Rozema T, Jeene PM, Blom GJ, van Dieren JM, Hulshof MCCM, van Laarhoven HWM, Grabsch HI, Lemmens VEPP, Tjan-Heijnen VCG, Nieuwenhuijzen GAP. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol 2020;59:895-903. [PMID: 32319845 DOI: 10.1080/0284186X.2020.1753889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R. Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol 2021;28:663-75. [PMID: 32648178 DOI: 10.1245/s10434-020-08761-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 2020;9:5881-8. [PMID: 32627960 DOI: 10.1002/cam4.3273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
77 Rades D, Bartscht T, Hunold P, Schmidberger H, König L, Debus J, Belka C, Homann N, Spillner P, Petersen C, Kuhnt T, Fietkau R, Ridwelski K, Karcher-Kilian K, Kranich A, Männikkö S, Schild SE, Maderer A, Moehler M. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). Strahlenther Onkol 2020;196:795-804. [PMID: 32533228 DOI: 10.1007/s00066-020-01646-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Münch S, Marr L, Feuerecker B, Dapper H, Braren R, Combs SE, Duma MN. Impact of 18F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients. Strahlenther Onkol 2020;196:787-94. [PMID: 32430661 DOI: 10.1007/s00066-020-01630-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Bhangoo RS, DeWees TA, Yu NY, Ding JX, Liu C, Golafshar MA, Rule WG, Vora SA, Ross HJ, Ahn DH, Beamer SE, Jaroszewski DE, Hallemeier CL, Liu W, Ashman JB, Sio TT. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol 2020;5:871-9. [PMID: 33083649 DOI: 10.1016/j.adro.2020.04.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
80 Xiao L, Czito BG, Pang Q, Hui Z, Jing S, Shan B, Wang J. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. J Cancer 2020;11:4605-13. [PMID: 32489478 DOI: 10.7150/jca.44447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
81 Ishida N, Osawa S, Miyazu T, Kaneko M, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Sugimoto K. Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience. J Clin Med 2020;9:E1509. [PMID: 32429571 DOI: 10.3390/jcm9051509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Eze C, Schmidt-Hegemann NS, Sawicki LM, Walter F, Manapov F. Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery. J Thorac Dis 2020;12:1624-7. [PMID: 32395301 DOI: 10.21037/jtd.2020.02.38] [Reference Citation Analysis]
83 Newman NB, Anderson JL, Sherry AD, Osmundson EC. Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer. J Thorac Dis 2020;12:2395-405. [PMID: 32642145 DOI: 10.21037/jtd.2020.03.93] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
84 Er P, Qian D, Zhang W, Zhang B, Wei H, Zhang T, Chen X, Wang Y, Zhao J, Wang Q, Pang Q, Wang P. The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy. Aging (Albany NY) 2020;12:6586-99. [PMID: 32330901 DOI: 10.18632/aging.102993] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, Dawson LA, Goodman KA. Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiother Oncol. 2020;148:194-200. [PMID: 32342878 DOI: 10.1016/j.radonc.2020.04.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
86 Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials 2020;248:120032. [PMID: 32304937 DOI: 10.1016/j.biomaterials.2020.120032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
87 Jung HK, Tae CH, Lee HA, Lee H, Don Choi K, Park JC, Kwon JG, Choi YJ, Hong SJ, Sung J, Chung WC, Kim KB, Kim SY, Song KH, Park KS, Jeon SW, Kim BW, Ryu HS, Lee OJ, Baik GH, Kim YS, Jung HY; Korean College of Helicobacter and Upper Gastrointestinal Research. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients. PLoS One 2020;15:e0231456. [PMID: 32275699 DOI: 10.1371/journal.pone.0231456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
88 Hu B, Jia F, Zhou H, Zhou T, Zhao Q, Chen Y, Li B, Huang W. Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma. J Cancer 2020;11:3693-700. [PMID: 32284766 DOI: 10.7150/jca.39033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
89 Cai G, Li C, Yu J, Meng X. Heart Dosimetric Parameters Were Associated With Cardiac Events and Overall Survival for Patients With Locally Advanced Esophageal Cancer Receiving Definitive Radiotherapy. Front Oncol 2020;10:153. [PMID: 32226770 DOI: 10.3389/fonc.2020.00153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Fan XW, Wang HB, Mao JF, Li L, Wu KL. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study. Cancer Med 2020;9:2812-9. [PMID: 32100452 DOI: 10.1002/cam4.2933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Huang C, Huang D, Zhu Y, Xie G, Wang H, Shi J, Jia B, Yuan Y, Zhang W. Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined with Radiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma. Transl Oncol 2020;13:100736. [PMID: 32092670 DOI: 10.1016/j.tranon.2019.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Li XY, Qu N, Wang XJ, Yang JX, Xin YY, Zhu JB, Bai X, Duan YB. Regulation of X-Ray Irradiation on the Activity and Expression Levels of CYP1A2 and CYP2E1 in Rats. Front Pharmacol 2019;10:1575. [PMID: 32047430 DOI: 10.3389/fphar.2019.01575] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Denkova AG, Liu H, Men Y, Eelkema R. Enhanced Cancer Therapy by Combining Radiation and Chemical Effects Mediated by Nanocarriers. Adv Therap 2020;3:1900177. [DOI: 10.1002/adtp.201900177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
94 Jethwa KR, Haddock MG, Tryggestad EJ, Hallemeier CL. The emerging role of proton therapy for esophagus cancer. J Gastrointest Oncol 2020;11:144-56. [PMID: 32175118 DOI: 10.21037/jgo.2019.11.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Esaki M, Minoda Y, Ihara E, Sakisaka S, Tsuruta S, Hosokawa T, Wada M, Hata Y, Suzuki S, Iwao A, Yamakawa S, Irie A, Akiho H, Ogawa Y. Efficacy of traction, using a clip-with-thread, for esophageal endoscopic submucosal dissection for esophageal lesions with fibrosis in an ex vivo pig training model. Turk J Gastroenterol 2020;31:58-64. [PMID: 32009615 DOI: 10.5152/tjg.2020.19207] [Reference Citation Analysis]
96 AbouAitah K, Stefanek A, Higazy IM, Janczewska M, Swiderska-Sroda A, Chodara A, Wojnarowicz J, Szałaj U, Shahein SA, Aboul-Enein AM, Abou-Elella F, Gierlotka S, Ciach T, Lojkowski W. Effective Targeting of Colon Cancer Cells with Piperine Natural Anticancer Prodrug Using Functionalized Clusters of Hydroxyapatite Nanoparticles. Pharmaceutics 2020;12:E70. [PMID: 31963155 DOI: 10.3390/pharmaceutics12010070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
97 Manzini G, Klotz U, Henne-Bruns D, Kremer M. Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials. World J Gastrointest Oncol 2020; 12(1): 113-123 [PMID: 31966919 DOI: 10.4251/wjgo.v12.i1.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Yang AJ, Choi SH, Byun HK, Kim HJ, Choi J, Lee YC, Lee SK, Park KR, Lee CG. Management of Clinical T1N0M0 Esophageal Cancer. Gut Liver. 2019;13:315-324. [PMID: 30600672 DOI: 10.5009/gnl18254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
99 Chen B, Li Q, Li Q, Qiu B, Xi M, Liu M, Hu Y, Zhu Y. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study. Oncologist 2020;25:308-e625. [PMID: 31880371 DOI: 10.1634/theoncologist.2019-0931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Kumble LD, Silver E, Oh A, Abrams JA, Sonett JR, Hur C. Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice. World J Meta-Anal 2019; 7(9): 406-417 [DOI: 10.13105/wjma.v7.i9.406] [Reference Citation Analysis]
101 Yaegashi A, Yoshida K, Suzuki N, Shimada I, Tani Y, Saijo Y, Toyama A. A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil. Int Cancer Conf J 2020;9:24-7. [PMID: 31950013 DOI: 10.1007/s13691-019-00394-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Mol Cancer Ther 2020;19:157-67. [PMID: 31597712 DOI: 10.1158/1535-7163.MCT-18-1302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
103 Iwabu J, Yamashita S, Takeshima H, Kishino T, Takahashi T, Oda I, Koyanagi K, Igaki H, Tachimori Y, Daiko H, Nakazato H, Nishiyama K, Lee YC, Hanazaki K, Ushijima T. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Sci Rep 2019;9:13347. [PMID: 31527639 DOI: 10.1038/s41598-019-50005-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
104 Park MI. Chemoradiotherapy for Esophageal Cancer. Korean J Helicobacter Up Gastrointest Res 2019;19:161-8. [DOI: 10.7704/kjhugr.2019.19.3.161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Netw Open 2019;2:e1910593. [PMID: 31483471 DOI: 10.1001/jamanetworkopen.2019.10593] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
106 Zhao Z, Zhang Y, Wang P, Wang X, Li M. The impact of the nodal status on the overall survival of non-surgical patients with esophageal squamous cell carcinoma. Radiat Oncol 2019;14:161. [PMID: 31481064 DOI: 10.1186/s13014-019-1365-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Wisdom AJ, Hong CS, Lin AJ, Xiang Y, Cooper DE, Zhang J, Xu ES, Kuo HC, Mowery YM, Carpenter DJ, Kadakia KT, Himes JE, Luo L, Ma Y, Williams N, Cardona DM, Haldar M, Diao Y, Markovina S, Schwarz JK, Kirsch DG. Neutrophils promote tumor resistance to radiation therapy. Proc Natl Acad Sci U S A 2019;116:18584-9. [PMID: 31462499 DOI: 10.1073/pnas.1901562116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
108 Zhu H, Pan W, Chen Y, Chen H, Zuo Y, Sun X. What Is the Optimal Radiotherapy Target Size for Non-Operable Esophageal Cancer? A Meta-Analysis. Oncol Res Treat 2019;42:470-9. [PMID: 31344698 DOI: 10.1159/000501594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Jain R, Yee JL, Shaikh T, Au C, Handorf E, Meyer JE, Dotan E. Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation. J Geriatr Oncol 2020;11:668-74. [PMID: 31257165 DOI: 10.1016/j.jgo.2019.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
110 Voeten DM, den Bakker CM, Heineman DJ, Ket JCF, Daams F, van der Peet DL. Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature. World J Surg 2019;43:1271-85. [PMID: 30607604 DOI: 10.1007/s00268-018-04901-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
111 Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd. Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). Oncologist 2020;25:e53-9. [PMID: 31227647 DOI: 10.1634/theoncologist.2018-0750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Lim C, Kang JK, Won WR, Park JY, Han SM, Le TN, Kim JC, Her J, Shin Y, Oh KT. Co-delivery of D-(KLAKLAK)2 Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy. Pharmaceutics 2019;11:E293. [PMID: 31234389 DOI: 10.3390/pharmaceutics11060293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
113 Klingelhöfer D, Zhu Y, Braun M, Brüggmann D, Schöffel N, Groneberg DA. A world map of esophagus cancer research: a critical accounting. J Transl Med 2019;17:150. [PMID: 31077194 DOI: 10.1186/s12967-019-1902-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
114 Li C, Wang X, Wang X, Han C, Wang P, Pang Q, Chen J, Sun X, Wang L, Zhang W, Lin Y, Ge X, Zhou Z, Ni W, Chang X, Liang J, Deng L, Wang W, Zhao Y, Xiao Z. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. BMC Cancer 2019;19:397. [PMID: 31036088 DOI: 10.1186/s12885-019-5544-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
115 Hofheinz F, Li Y, Steffen IG, Lin Q, Lili C, Hua W, van den Hoff J, Zschaeck S. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:1485-94. [PMID: 30949816 DOI: 10.1007/s00259-019-04307-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
116 Hojo H, Dohmae T, Hotta K, Kageyama SI, Baba H, Kohno R, Motegi A, Tsuchihara K, Akimoto T. Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak. Acta Oncol 2019;58:475-82. [PMID: 30632869 DOI: 10.1080/0284186X.2018.1555373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
117 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
118 Yamashita K, Mine S, Toihata T, Fukudome I, Okamura A, Yuda M, Hayami M, Imamura Y, Watanabe M. The usefulness of three-dimensional video-assisted thoracoscopic esophagectomy in esophageal cancer patients. Esophagus 2019;16:272-7. [PMID: 30888533 DOI: 10.1007/s10388-019-00661-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
119 Li C, Ni W, Wang X, Zhou Z, Deng W, Chang X, Chen D, Feng Q, Liang J, Wang X, Deng L, Wang W, Bi N, Zhang T, Xiao Z. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol 2019;14:48. [PMID: 30876442 DOI: 10.1186/s13014-019-1249-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Yijie Q, Xuejun W, Yuanyao X, Yongqiong N, Jianxin Y, Yabin D, Xiangyang L. Effect of X-ray irradiation on pharmacokinetics of irinotecan hydrochloride and expression of CES1 and CYP3A1 in rats. Fundam Clin Pharmacol 2019;33:558-66. [PMID: 30811654 DOI: 10.1111/fcp.12456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Chen WK, Chen CA, Chi CW, Li LH, Lin CP, Shieh HR, Hsu ML, Ko CC, Hwang JJ, Chen YJ. Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy. J Clin Med 2019;8:E187. [PMID: 30764514 DOI: 10.3390/jcm8020187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
122 Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy. Biomed Res Int 2019;2019:1263050. [PMID: 30834254 DOI: 10.1155/2019/1263050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
123 Pereira-Oliveira M, Reis-Mendes A, Carvalho F, Remião F, Bastos ML, Costa VM. Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells. Biomolecules 2019;9:E21. [PMID: 30634681 DOI: 10.3390/biom9010021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
124 Huang C, Zhu Y, Li Q, Zhang W, Liu H, Zhang W, Hu Y, Yuan Y, Liu M. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. Cancer Med 2019;8:28-39. [PMID: 30600600 DOI: 10.1002/cam4.1788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kim H, Oh D, Ahn YC, Park K, Ahn MJ, Lee SH, Sun JM, Shim YM, Zo JI, Choi YS, Kim HK, Cho JH. Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. Radiat Oncol 2018;13:245. [PMID: 30547802 DOI: 10.1186/s13014-018-1196-6] [Reference Citation Analysis]
126 Huang ZH, Ma XW, Zhang J, Li X, Lai NL, Zhang SX. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. BMC Cancer 2018;18:1170. [PMID: 30477458 DOI: 10.1186/s12885-018-5040-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
127 Semenkovich TR, Samson PP, Hudson JL, Subramanian M, Meyers BF, Kozower BD, Kreisel D, Patterson GA, Robinson CG, Bradley JD, Puri V. Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes? Ann Thorac Surg 2019;107:903-11. [PMID: 30444988 DOI: 10.1016/j.athoracsur.2018.09.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
128 Bracken-Clarke D, Farooq AR, Horgan AM. Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population. Curr Oncol Rep 2018;20:99. [PMID: 30426245 DOI: 10.1007/s11912-018-0745-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
129 Ai D, Chen Y, Liu Q, Zhang J, Deng J, Zhu H, Ren W, Zheng X, Li Y, Wei S, Ye J, Zhou J, Lin Q, Luo H, Cao J, Li J, Huang G, Wu K, Fan M, Yang H, Zhu Z, Zhao W, Li L, Fan J, Badakhshi H, Zhao K. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). BMJ Open 2018;8:e020785. [PMID: 30344165 DOI: 10.1136/bmjopen-2017-020785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
130 Zhu H, Ge X, Lu Y, Zuo Y, Qin Q, Sun X, Yang M. Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. Oncol Lett 2019;17:594-602. [PMID: 30655806 DOI: 10.3892/ol.2018.9564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
131 Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Baba S, Sugimura H, Miyajima H, Furuta T. High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. Oncotarget 2018;9:34876-88. [PMID: 30405881 DOI: 10.18632/oncotarget.26172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
132 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
133 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43. [PMID: 30171414 DOI: 10.1007/s10388-018-0642-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 29.3] [Reference Citation Analysis]
134 Münch S, Pigorsch SU, Devečka M, Dapper H, Weichert W, Friess H, Braren R, Combs SE, Habermehl D. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol 2018;13:139. [PMID: 30068371 DOI: 10.1186/s13014-018-1085-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
135 Zhu W, Zhang Y, Kong L, Huang Y, Zheng J, Wang R, Li M, Yu J. 18F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. Onco Targets Ther 2018;11:4345-53. [PMID: 30100740 DOI: 10.2147/OTT.S160456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
137 Sugase T, Makino T, Yamasaki M, Tanaka K, Hashimoto T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mano M, Morii E, Mori M, Doki Y. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus 2018. [PMID: 29909488 DOI: 10.1007/s10388-018-0626-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Li CC, Chen CY, Chien CR. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis. Medicine (Baltimore) 2018;97:e10928. [PMID: 29851829 DOI: 10.1097/MD.0000000000010928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
140 Walter F, Böckle D, Schmidt-Hegemann NS, Köpple R, Gerum S, Boeck S, Angele M, Belka C, Roeder F. Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. Radiat Oncol 2018;13:93. [PMID: 29769143 DOI: 10.1186/s13014-018-1044-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
141 Wang W, Xing D, Song Y, Liu F. Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2018;97:e0164. [PMID: 29561425 DOI: 10.1097/MD.0000000000010164] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
142 Li Y, Hofheinz F, Furth C, Lili C, Hua W, Ghadjar P, Zschaeck S. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1752-61. [PMID: 29679113 DOI: 10.1007/s00259-018-3996-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
143 Zhou YC, Chen LL, Xu HB, Sun Q, Zhang Q, Cai HF, Jiang H. Aging-related prognosis analysis of definitive radiotherapy for very elderly esophageal cancer. Cancer Med 2018;7:1837-44. [PMID: 29608256 DOI: 10.1002/cam4.1456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
144 Miyazaki T, Sohda M, Sakai M, Kumakura Y, Yoshida T, Kuriyama K, Yokobori T, Miyazaki M, Hirato J, Okumura T, Ishikawa H, Sakurai H, Kuwano H. Multimodality Therapy Including Proton Beam Therapy for AFP Producing Esophageal Cancer with Multiple Liver Metastases. Intern Med 2018;57:2333-9. [PMID: 29607947 DOI: 10.2169/internalmedicine.0270-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
145 Fan B, Fan P, Kong L, Sun X, Zhao S, Sun X, Fu Z, Zheng J, Ma L, Wang S, Hu M, Yu J. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget 2017;8:34498-506. [PMID: 28404900 DOI: 10.18632/oncotarget.15606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
146 Park JH, Kim KY, Song HY, Cho YC, Kim PH, Tsauo J, Kim MT, Jun EJ, Jung HY, Kim SB, Kim JH. Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients. Acta Radiol 2018;59:313-21. [PMID: 28573925 DOI: 10.1177/0284185117713351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
147 Chen Y, Zhu Z, Zhao W, Li L, Ye J, Wu C, Tang H, Lin Q, Li J, Xia Y, Li Y, Zhou J, Zhao K. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol. Radiat Oncol 2018;13:33. [PMID: 29482649 DOI: 10.1186/s13014-018-0979-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Xia Y, Li YH, Chen Y, Liu Q, Zhang JH, Deng JY, Ai TS, Zhu HT, Badakhshi H, Zhao KL. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Int J Clin Oncol 2018;23:458-65. [PMID: 29435872 DOI: 10.1007/s10147-018-1240-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
149 Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary Approach to the Management of Esophageal Malignancies. World J Surg 2017;41:1726-33. [PMID: 28361298 DOI: 10.1007/s00268-017-4009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
150 Crosby TDL. Challenging disease, challenging trial, challenging interpretation. The Lancet Gastroenterology & Hepatology 2018;3:78-9. [DOI: 10.1016/s2468-1253(17)30393-x] [Reference Citation Analysis]
151 Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis. Radiat Oncol 2018;13:12. [PMID: 29357883 DOI: 10.1186/s13014-018-0958-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
152 Zhang P, Xi M, Li QQ, Hu YH, Guo X, Zhao L, Liu H, Liu SL, Luo LL, Liu Q, Liu MZ. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Oncotarget 2016;7:44686-94. [PMID: 27183916 DOI: 10.18632/oncotarget.9301] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
153 Adenis A, Piessen G, Azria D. Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence? Ann Transl Med 2017;5:503. [PMID: 29299464 DOI: 10.21037/atm.2017.10.27] [Reference Citation Analysis]
154 Saito H, Ohta A, Abe E, Kaidu M, Shioi M, Nakano T, Oshikane T, Tanaka K, Maruyama K, Kushima N, Tanabe S, Utsunomiya S, Sasamoto R, Aoyama H. Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients. Clin Transl Radiat Oncol 2018;9:12-7. [PMID: 29594245 DOI: 10.1016/j.ctro.2017.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
155 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
156 Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol 2017;3:1520-8. [PMID: 28687830 DOI: 10.1001/jamaoncol.2017.1598] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 16.2] [Reference Citation Analysis]
157 Qu XM, Biagi JJ, Hopman WM, Mahmud A. Shifting practice in definitive chemoradiation for localized esophageal cancer. Curr Oncol 2017;24:e379-87. [PMID: 29089808 DOI: 10.3747/co.24.3677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
158 Zhu Y, Zhang W, Li Q, Li Q, Qiu B, Liu H, Liu M, Hu Y. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma. J Cancer 2017;8:3657-66. [PMID: 29151952 DOI: 10.7150/jca.20053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
159 Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. J Cancer 2017;8:3242-50. [PMID: 29158796 DOI: 10.7150/jca.20835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
160 Ji Y, Du X, Tian Y, Sheng L, Cheng L, Chen Y, Qiu G, Zhou X, Bao W, Zhang D, Chen M. A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Oncotarget 2017;8:83022-9. [PMID: 29137320 DOI: 10.18632/oncotarget.20938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
161 Ebrahimi Fard A, Tavakoli MB, Salehi H, Emami H. Synergetic effects of Docetaxel and ionizing radiation reduced cell viability on MCF-7 breast cancer cell. Appl Cancer Res 2017;37. [DOI: 10.1186/s41241-017-0035-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
162 Münch S, Oechsner M, Combs SE, Habermehl D. DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. Radiat Oncol 2017;12:128. [PMID: 28806990 DOI: 10.1186/s13014-017-0871-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
163 Zhang W, Wang Q, Li T, Lv J, Liu H, Jia X, Liu B, Fan Y, Wang Y, Wang J, Wu L, Lang J. External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. J Contemp Brachytherapy 2017;9:330-7. [PMID: 28951752 DOI: 10.5114/jcb.2017.69334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 351] [Article Influence: 49.8] [Reference Citation Analysis]
165 Servagi-Vernat S, Créhange G, Bonnetain F, Mertens C, Brain E, Bosset JF. Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE). BMC Cancer 2017;17:483. [PMID: 28705182 DOI: 10.1186/s12885-017-3465-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
166 Deng Y, Bian C, Tao H, Zhang H. Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Oncotarget 2017;8:79662-9. [PMID: 29108346 DOI: 10.18632/oncotarget.19030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
167 Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis 2017;9:S792-8. [PMID: 28815076 DOI: 10.21037/jtd.2017.05.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
168 Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M. Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2017;44:1813-22. [PMID: 28600646 DOI: 10.1007/s00259-017-3742-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
169 Sato Y, Gonda K, Harada M, Tanisaka Y, Arai S, Mashimo Y, Iwano H, Sato H, Ryozawa S, Takahashi T, Sakuramoto S, Shibata M. Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Rep 2017;7:79-84. [PMID: 28685065 DOI: 10.3892/br.2017.924] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
170 Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286-94. [PMID: 29113302 DOI: 10.18632/oncotarget.17925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
171 Huang BT, Wu LL, Guo LJ, Xu LY, Huang RH, Lin PX, Chen JZ, Li DR, Chen CZ. Radiobiological evaluation of simultaneously dose-escalated versus non-escalated intensity-modulated radiation therapy for patients with upper thoracic esophageal cancer. Onco Targets Ther 2017;10:2209-17. [PMID: 28458564 DOI: 10.2147/OTT.S132388] [Reference Citation Analysis]
172 Kumaran D, John S, Isiah R, Das S. Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. J Gastrointest Cancer 2016;47:313-7. [PMID: 27146042 DOI: 10.1007/s12029-016-9825-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
174 Desbordes P, Ruan S, Modzelewski R, Pineau P, Vauclin S, Gouel P, Michel P, Di Fiore F, Vera P, Gardin I. Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier. PLoS One 2017;12:e0173208. [PMID: 28282392 DOI: 10.1371/journal.pone.0173208] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
175 Sun L, Zhao F, Zeng Y, Yi C. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis. Med Sci Monit 2017;23:889-910. [PMID: 28214903 DOI: 10.12659/msm.903328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
176 Li T, Zhang W, Lv J, Liu H, Wang Q, Jia X, Liu B, Lang J. Safety and outcome of external beam radiation and neutron brachytherapy in elderly patients with esophageal squamous cell cancer. J Contemp Brachytherapy 2017;9:36-43. [PMID: 28344602 DOI: 10.5114/jcb.2017.65839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
177 Oh D, Noh JM, Nam H, Lee H, Kim TG, Ahn YC. High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma. Medicine (Baltimore) 2016;95:e4591. [PMID: 27537591 DOI: 10.1097/MD.0000000000004591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
178 Peng YB, Zhao ZL, Liu T, Xie GJ, Jin C, Deng TG, Sun Y, Li X, Hu XX, Zhang XB, Ye M, Tan WH. A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance. ChemMedChem 2017;12:250-6. [PMID: 28098432 DOI: 10.1002/cmdc.201600538] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
179 Matsumoto K, Yamasaki N, Tsuchiya T, Miyazaki T, Kamohara R, Hatachi G, Nagayasu T. Double stenting with silicone and metallic stents for malignant airway stenosis. Surg Today 2017;47:1027-35. [PMID: 28078443 DOI: 10.1007/s00595-016-1466-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
180 Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D, Sahu A, Shah S, Ghosh-Laskar S, Patil PS, Mehta SA, Jambhekar N, Mahajan A, Purandare N. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncol Res 2016;23:183-95. [PMID: 27053347 DOI: 10.3727/096504016X14537290676865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
181 Wirsdörfer F, Jendrossek V. The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. Front Immunol 2016;7:591. [PMID: 28018357 DOI: 10.3389/fimmu.2016.00591] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 7.5] [Reference Citation Analysis]
182 Verma V, Moreno AC, Lin SH. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 2016;5:E91. [PMID: 27775643 DOI: 10.3390/jcm5100091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
183 Kim HJ, Suh YG, Lee YC, Lee SK, Shin SK, Cho BC, Lee CG. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Res Treat 2017;49:669-77. [PMID: 27737537 DOI: 10.4143/crt.2016.354] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
184 Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun 2016;7:13019. [PMID: 27698471 DOI: 10.1038/ncomms13019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
185 Bernards N, Haj Mohammad N, Creemers GJ, Rozema T, Roukema JA, Nieuwenhuijzen GA, van Laarhoven HW, van der Sangen M, Lemmens VE. Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013. Acta Oncol 2016;55:1161-7. [PMID: 27174793 DOI: 10.1080/0284186X.2016.1176249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
186 Kapoor R, Bansal A, Kumar S, Miriyala RT. Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. Indian J Palliat Care 2016;22:288-94. [PMID: 27559257 DOI: 10.4103/0973-1075.185037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
187 Ito H, Itasaka S, Sakanaka K, Araki N, Mizowaki T, Hiraoka M. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res 2017;58:106-13. [PMID: 27475126 DOI: 10.1093/jrr/rrw078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
188 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Cox S, Powell C, Carter B, Hurt C, Mukherjee S, Crosby TD. Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. Br J Cancer 2016;115:172-7. [PMID: 27328311 DOI: 10.1038/bjc.2016.129] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
190 Créhange G, Conroy T. The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future? J Thorac Dis 2016;8:1014-8. [PMID: 27293806 DOI: 10.21037/jtd.2016.03.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78:91-99. [PMID: 27193097 DOI: 10.1007/s00280-016-3062-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
192 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
193 Shakespeare TP, Wilcox SW, Aherne NJ. Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation? Onco Targets Ther 2016;9:2819-24. [PMID: 27274277 DOI: 10.2147/OTT.S105174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
194 Ji Y, Qiu G, Sheng L, Sun X, Zheng Y, Chen M, Du X. A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis 2016;8:451-8. [PMID: 27076940 DOI: 10.21037/jtd.2016.02.70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
195 Fulton BA, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A, Grose D. Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. J Gastrointest Oncol 2016;7:166-72. [PMID: 27034782 DOI: 10.3978/j.issn.2078-6891.2015.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Shakespeare TP, Wilcox SW, Aherne NJ. Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation? Onco Targets Ther 2016;9:1635-9. [PMID: 27073327 DOI: 10.2147/OTT.S102327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
197 Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Tachibana H, Uemura N, Tajika M, Niwa Y, Muto M, Muro K. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol 2016;21:890-8. [PMID: 26980212 DOI: 10.1007/s10147-016-0963-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
198 Sakanaka K, Ishida Y, Itasaka S, Ezoe Y, Aoyama I, Miyamoto S, Horimatsu T, Muto M, Hiraoka M. Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy. Int J Clin Oncol 2016;21:899-908. [PMID: 26936851 DOI: 10.1007/s10147-016-0967-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
199 Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2016;89:20150476. [PMID: 26891913 DOI: 10.1259/bjr.20150476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
200 Hamdache A, Saadi S. A stochastic nominal control optimizing the adoptive immunotherapy for cancer using tumor-infiltrating lymphocytes. Int J Dynam Control 2017;5:783-98. [DOI: 10.1007/s40435-016-0228-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Li M, Zhang X, Zhao F, Luo Y, Kong L, Yu J. Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiat Oncol 2016;11:18. [PMID: 26846932 DOI: 10.1186/s13014-016-0589-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
202 Smith WH, Pintova S, DiMaio CJ, Manolas P, Lee DS, Hiotis SP, Kartsonis M, Holcombe RF, Dharmarajan KV. An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med 2015;2015:941508. [PMID: 26770853 DOI: 10.1155/2015/941508] [Reference Citation Analysis]
203 Qu X, Biagi J, Banashkevich A, Mercer CD, Tremblay L, Mahmud A. Management and outcomes of localized esophageal and gastroesophageal junction cancer in older patients. Curr Oncol 2015;22:e435-42. [PMID: 26715880 DOI: 10.3747/co.22.2661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
204 Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB 3rd. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. Int J Radiat Oncol Biol Phys 2016;94:738-46. [PMID: 26972646 DOI: 10.1016/j.ijrobp.2015.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
205 Servagi-Vernat S, Créhange G, Roullet B, Guimas V, Maingon P, Puyraveau M, Bosset JF. Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer. Drugs Aging 2015;32:487-93. [PMID: 26038198 DOI: 10.1007/s40266-015-0275-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
206 Carrington R, Staffurth J, Warren S, Partridge M, Hurt C, Spezi E, Gwynne S, Hawkins MA, Crosby T. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiat Oncol 2015;10:236. [PMID: 26586375 DOI: 10.1186/s13014-015-0537-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
207 Shaikh T, Zaki MA, Dominello MM, Handorf E, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncol 2016;55:303-8. [PMID: 26581671 DOI: 10.3109/0284186X.2015.1110252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
208 Nakajima M, Domeki Y, Satomura H, Takahashi M, Sugawara A, Muroi H, Sasaki K, Yamaguchi S, Miyazaki T, Kuwano H, Kato H. Salvage lymphadenectomy for recurrent esophageal cancer after chemoradiotherapy. Int Surg 2014;99:452-7. [PMID: 25058783 DOI: 10.9738/INTSURG-D-13-00261.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
209 Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM, Kreisel D, Krupnick AS, Patterson GA, Meyers BF. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. Ann Thorac Surg 2016;101:200-8; discussion 208-10. [PMID: 26507424 DOI: 10.1016/j.athoracsur.2015.09.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
210 Behrens A, Ell C, Lordick F. Perioperative and Palliative Chemotherapy for Esophageal Cancer. Viszeralmedizin 2015;31:341-6. [PMID: 26989390 DOI: 10.1159/000438470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Jingu K, Umezawa R, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol 2016;21:276-82. [PMID: 26324841 DOI: 10.1007/s10147-015-0896-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
212 Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, Nakagawa K. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol 2015;10:171. [PMID: 26269033 DOI: 10.1186/s13014-015-0482-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
213 O'Sullivan KE, Hurley ET, Hurley JP. Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterol Res Pract 2015;2015:518281. [PMID: 26246803 DOI: 10.1155/2015/518281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
214 Toulba A, Bakkali H, Boutayeb S, Kebdani T, Ahid S, Benjaafar N. [Curietherapy in the palliative treatment of esophageal cancer]. Pan Afr Med J 2015;20:59. [PMID: 26090017 DOI: 10.11604/pamj.2015.20.59.5881] [Reference Citation Analysis]
215 Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015;10:e0128616. [PMID: 26046353 DOI: 10.1371/journal.pone.0128616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
216 Nkhali L, Thureau S, Edet-Sanson A, Doyeux K, Benyoucef A, Gardin I, Michel P, Vera P, Dubray B. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses. Acta Oncol 2015;54:909-15. [PMID: 25417733 DOI: 10.3109/0284186X.2014.973062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
217 Chang CH, Liu SY, Chi CW, Yu HL, Chang TJ, Tsai TH, Lee TW, Chen YJ. External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics. Int J Nanomedicine 2015;10:3641-9. [PMID: 26056445 DOI: 10.2147/IJN.S80302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
218 Le QT, Shirato H, Giaccia AJ, Koong AC. Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res 2015;21:3393-401. [PMID: 25991820 DOI: 10.1158/1078-0432.CCR-14-1191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
219 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
220 Hsieh CH, Hou ML, Wang LY, Tai HC, Tsai TH, Chen YJ. Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. BMC Cancer 2015;15:316. [PMID: 25928348 DOI: 10.1186/s12885-015-1344-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
221 Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, Debus J, Sterzing F. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res 2015;56:742-9. [PMID: 25907360 DOI: 10.1093/jrr/rrv022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
222 Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR, Mamon HJ, Thomas CR Jr, Goodman KA. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. Int J Radiat Oncol Biol Phys 2015;92:911-20. [PMID: 26104943 DOI: 10.1016/j.ijrobp.2015.03.030] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
223 Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, Jeong JU, Song JY, Nam TK. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J 2015;33:12-20. [PMID: 25874173 DOI: 10.3857/roj.2015.33.1.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
224 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Nakamura K, Fukuda H;  Japan Clinical Oncology Group. Randomized study of low-dose vs standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407-412. [PMID: 25640628 DOI: 10.1111/cas.12622] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 10.9] [Reference Citation Analysis]
226 Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, Mizumoto M, Okumura T, Sakae T, Sakurai H. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res 2015;56:568-76. [PMID: 25755255 DOI: 10.1093/jrr/rrv001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
227 Zhang XD, Luo Z, Chen J, Song S, Yuan X, Shen X, Wang H, Sun Y, Gao K, Zhang L, Fan S, Leong DT, Guo M, Xie J. Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance. Sci Rep 2015;5:8669. [PMID: 25727895 DOI: 10.1038/srep08669] [Cited by in Crossref: 164] [Cited by in F6Publishing: 165] [Article Influence: 23.4] [Reference Citation Analysis]
228 Zhou ZG, Zhen CJ, Bai WW, Zhang P, Qiao XY, Liang JL, Gao XS, Wang SS. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiat Oncol 2015;10:54. [PMID: 25888966 DOI: 10.1186/s13014-015-0358-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
229 Liu H, Yang W, Gao H, Jiang T, Gu B, Dong Q, Xu W, Wu S, Sun X. Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair. Onco Targets Ther 2015;8:509-18. [PMID: 25750543 DOI: 10.2147/OTT.S76958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
230 Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, Gardin I, Di Fiore F, Michel P, Vera P. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. Eur J Nucl Med Mol Imaging 2015;42:858-67. [PMID: 25680400 DOI: 10.1007/s00259-015-3004-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
231 Cao C, Luo J, Gao L, Xu G, Yi J, Huang X, Wang K, Zhang S, Qu Y, Li S, Xiao J, Zhang Z. Definitive intensity-modulated radiotherapy compared with definitive conventional radiotherapy in cervical oesophageal squamous cell carcinoma. Radiol Med 2015;120:603-10. [PMID: 25644251 DOI: 10.1007/s11547-015-0510-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
232 Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015;6:45-52. [PMID: 25642337 DOI: 10.3978/j.issn.2078-6891.2014.054] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
233 Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015;6:53-9. [PMID: 25642338 DOI: 10.3978/j.issn.2078-6891.2014.099] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
234 Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015;6:39-44. [PMID: 25642336 DOI: 10.3978/j.issn.2078-6891.2014.101] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
235 Miriyala R, Kapoor R, Bahl A, Bhattacharya A, Bahl A, Tomar P. Acute effects of chemoradiation on cardiac function in oesophageal cancer: a MUGA scan and echo-based study. Heart Asia 2015;7:26-30. [PMID: 27326217 DOI: 10.1136/heartasia-2015-010622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
236 Ma K, Wang Q, Li T, Liu H, Liu B, Jia X, Li S, Lang J, Zhang M. A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. Radiat Oncol 2014;9:294. [PMID: 25515326 DOI: 10.1186/s13014-014-0294-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
237 Alzahrani AM, Bazarbashi SN, Rahal MM, Al-Shehri AS, Aljubran AH, Kandil MS, Zekri JE, Al Olayan AA, Alsharm AA, Yamani NM, Alomary IS, Fagih MA; Saudi Oncology Society. Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. Saudi Med J 2014;35:1545-9. [PMID: 25491227] [Reference Citation Analysis]
238 Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M, Sumita K, Tanigawa N. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol 2015;88:20140168. [PMID: 25429644 DOI: 10.1259/bjr.20140168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
239 Zhang P, Xi M, Zhao L, Li QQ, He LR, Liu SL, Shen JX, Liu MZ. Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone. Radiat Oncol 2014;9:256. [PMID: 25424871 DOI: 10.1186/s13014-014-0256-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
240 Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, Combs SE, Fakhrian K. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlenther Onkol. 2015;191:153-160. [PMID: 25404062 DOI: 10.1007/s00066-014-0779-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
241 Alfieri R, Pintacuda G, Cagol M, Occhipinti T, Capraro I, Scarpa M, Zanchettin G, Cavallin F, Michelotto M, Giacomelli L, Ancona E, Castoro C. Oesophageal cancer: assessment of tumour response to chemoradiotherapy with tridimensional CT. Radiol Med 2015;120:430-9. [PMID: 25354813 DOI: 10.1007/s11547-014-0466-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
242 Liu M, Zhao K, Chen Y, Jiang GL. Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis. Radiat Oncol 2014;9:232. [PMID: 25344056 DOI: 10.1186/s13014-014-0232-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
243 Jeong Y, Kim JH. WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. Gastrointestinal Intervention 2014. [DOI: 10.1016/j.gii.2014.09.003] [Reference Citation Analysis]
244 Hayashi Y, Nishida T, Tsujii M, Tsutsui S, Yamamoto K, Isohashi F, Yamasaki M, Miyata H, Kato M, Yamada T. Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma. BMC Cancer. 2014;14:706. [PMID: 25253238 DOI: 10.1186/1471-2407-14-706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
245 Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32:3400-5. [PMID: 25225435 DOI: 10.1200/JCO.2014.56.7156] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 7.4] [Reference Citation Analysis]
246 Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191. [PMID: 25175056 DOI: 10.1186/1748-717X-9-191] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
247 Song S, Chang D, Cui Y, Hu J, Gong M, Ma K, Ding F, Liu ZH, Wang TY. New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice. Thorac Cancer 2014;5:417-24. [PMID: 26767033 DOI: 10.1111/1759-7714.12112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
248 Zhang P, Xi M, Zhao L, Shen JX, Li QQ, He LR, Liu SL, Liu MZ. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? PLoS One 2014;9:e105270. [PMID: 25133495 DOI: 10.1371/journal.pone.0105270] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
249 Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol 2014; 6(8): 263-274 [PMID: 25132924 DOI: 10.4251/wjgo.v6.i8.263] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
250 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
251 Gupta A, Roy S, Majumdar A, Hazra A, Mallik C. A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer. Indian J Med Paediatr Oncol 2014;35:54-9. [PMID: 25006285 DOI: 10.4103/0971-5851.133722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
252 Wang Q, Li T, Liu H, Jia X, Liu B, Wan X, Lang J. The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. Radiat Oncol 2014;9:99. [PMID: 24774780 DOI: 10.1186/1748-717X-9-99] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
253 Deleon MC, Ammakkanavar NR, Matei D. Adjuvant therapy for endometrial cancer. J Gynecol Oncol 2014;25:136-47. [PMID: 24761218 DOI: 10.3802/jgo.2014.25.2.136] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
254 Vera P, Dubray B, Palie O, Buvat I, Hapdey S, Modzelewski R, Benyoucef A, Rousseau C, Meyer ME, Bardet S, Gardin I, Fiore FD, Michel P. Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. EJNMMI Res 2014;4:12. [PMID: 24602385 DOI: 10.1186/2191-219X-4-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
255 Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassivi SD, Montero AJ, Schefter TE; American College of Surgeons Oncology Group. Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Ann Oncol 2014;25:1039-44. [PMID: 24562448 DOI: 10.1093/annonc/mdu091] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
256 Honing J, Smit JK, Muijs CT, Burgerhof JGM, de Groot JW, Paardekooper G, Muller K, Woutersen D, Legdeur MJC, Fiets WE, Slot A, Beukema JC, Plukker JTM, Hospers GAP. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25:638-43. [PMID: 24492674 DOI: 10.1093/annonc/mdt589] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
257 Hafeez S, Bedford JL, Tait DM, Hawkins MA. Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. Acta Oncol 2014;53:149-54. [PMID: 23517249 DOI: 10.3109/0284186X.2013.776174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
258 Kannan RA. Feasibility of Concurrent Chemoradiation in Patients treated for Esophageal Carcinoma: A Single Institutional Experience. Euroasian J Hepatogastroenterol 2014;4:11-3. [PMID: 29264312 DOI: 10.5005/jp-journals-10018-1089] [Reference Citation Analysis]
259 Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol 2013; 19(48): 9447-9452 [PMID: 24409075 DOI: 10.3748/wjg.v19.i48.9447] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
260 Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014;105:202-10. [PMID: 24219164 DOI: 10.1111/cas.12322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
261 Xu HY, DU ZD, Zhou L, Yu M, Ding ZY, Lu Y. Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. Oncol Lett 2014;7:260-6. [PMID: 24348860 DOI: 10.3892/ol.2013.1694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
262 Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodríguez R, Zheng J, Wang L. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. Onco Targets Ther 2013;6:1589-96. [PMID: 24235844 DOI: 10.2147/OTT.S50945] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
263 Ahmad S, Adler DG. First reported case of intentional use of a duodenal stent to treat gastric outlet obstruction prior to pancreaticoduodenectomy in a patient with pancreatic cancer. Dig Dis Sci 2014;59:489-92. [PMID: 24114048 DOI: 10.1007/s10620-013-2895-3] [Reference Citation Analysis]
264 Adenis A, Tresch E, Dewas S, Romano O, Messager M, Amela E, Clisant S, Kramar A, Mariette C, Mirabel X. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013;13:413. [PMID: 24010566 DOI: 10.1186/1471-2407-13-413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
265 Powathil GG, Adamson DJ, Chaplain MA. Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model. PLoS Comput Biol 2013;9:e1003120. [PMID: 23874170 DOI: 10.1371/journal.pcbi.1003120] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
266 Chi CW, Chen CC, Chen YJ. Therapeutic and radiosensitizing effects of armillaridin on human esophageal cancer cells. Evid Based Complement Alternat Med 2013;2013:459271. [PMID: 23864890 DOI: 10.1155/2013/459271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
267 Platz TA, Nurkin SJ, Fong MK, Groman A, Flaherty L, Malhotra U, Levea CM, Yendamuri S, Warren GW, Nava HR. Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma. J Gastrointest Oncol. 2013;4:137-143. [PMID: 23730509 DOI: 10.3978/j.issn.2078-6891.2013.007] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
268 Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 2013;17:1359-69. [PMID: 23715646 DOI: 10.1007/s11605-013-2223-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
269 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Hara J, Yamamura T, Inoue M. Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Mol Clin Oncol 2013;1:773-9. [PMID: 24649245 DOI: 10.3892/mco.2013.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
270 Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest 2013;123:2576-89. [PMID: 23676499 DOI: 10.1172/JCI68143] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
271 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
272 Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J, Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2013;4:174-85. [PMID: 28920199 DOI: 10.1111/j.1759-7714.2012.00166.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013;61:330-5. [PMID: 23568356 DOI: 10.1007/s11748-013-0246-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
274 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
275 Kim YS, Lee CG, Kim KH, Kim T, Lee J, Cho Y, Koom WS. Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiat Oncol J 2012;30:182-8. [PMID: 23346537 DOI: 10.3857/roj.2012.30.4.182] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
276 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
277 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
278 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
279 Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2012;9:833-7. [PMID: 23155356 DOI: 10.7150/ijms.4914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
280 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
281 Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD; SWOG GI Committee. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 2012;7:906-12. [PMID: 22481235 DOI: 10.1097/JTO.0b013e31824c7bed] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
282 Chen Y, Wu X, Bu S, He C, Wang W, Liu J, Guo W, Tan B, Wang Y, Wang J. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci. 2012;103:1979-1984. [PMID: 22845557 DOI: 10.1111/j.1349-7006.2012.02393.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
283 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
284 Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol 2012;10:173. [PMID: 22920951 DOI: 10.1186/1477-7819-10-173] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
285 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
286 Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, Jiang GL. Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol 2012;7:142. [PMID: 22913676 DOI: 10.1186/1748-717X-7-142] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
287 Yano T, Muto M, Yoshimura K, Niimi M, Ezoe Y, Yoda Y, Yamamoto Y, Nishisaki H, Higashino K, Iishi H. Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer. Radiat Oncol 2012;7:113. [PMID: 22824179 DOI: 10.1186/1748-717X-7-113] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
288 Gao Y, Chen XF, Wu QQ, Hu ZB, Yang Y, Liu YQ, Liu BR; Cochrane Upper GI and Pancreatic Diseases Group. Postoperative chemotherapy or radiotherapy for esophageal cancer. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd009967] [Reference Citation Analysis]
289 Yu C, Zhang Q, Zhang HY, Zhang X, Huo X, Cheng E, Wang DH, Arbiser JL, Spechler SJ, Souza RF. Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2012;303:G561-9. [PMID: 22744336 DOI: 10.1152/ajpgi.00033.2012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
290 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
291 Torrente S, Turri L, Deantonio L, Cena T, Gambaro G, Magnani C, Krengli M. Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients. Rep Pract Oncol Radiother 2012;17:226-32. [PMID: 24377028 DOI: 10.1016/j.rpor.2012.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
292 Yoda Y, Yano T, Kaneko K, Tsuruta S, Oono Y, Kojima T, Minashi K, Ikematsu H, Ohtsu A. Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer. Surg Endosc 2012;26:2877-83. [PMID: 22543993 DOI: 10.1007/s00464-012-2273-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
293 Wolf MC, Zehentmayr F, Schmidt M, Hölzel D, Belka C. Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol 2012;7:60. [PMID: 22501022 DOI: 10.1186/1748-717X-7-60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
294 Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol 2012;29:3017-23. [PMID: 22476809 DOI: 10.1007/s12032-012-0228-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
295 Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, Junginger T. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer 2012;12:70. [PMID: 22336151 DOI: 10.1186/1471-2407-12-70] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
296 Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher A, Müller RP. Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol 2012;188:226-32. [PMID: 22318327 DOI: 10.1007/s00066-011-0039-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
297 Nomura M, Kodaira T, Furutani K, Tachibana H, Tomita N, Goto Y. Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. Br J Radiol 2012;85:813-8. [PMID: 22253344 DOI: 10.1259/bjr/13604628] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
298 Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012;188:136-142. [PMID: 22218502 DOI: 10.1007/s00066-011-0023-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
299 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
300 Hawkins MA, Aitken A, Hansen VN, McNair HA, Tait DM. Cone beam CT verification for oesophageal cancer - impact of volume selected for image registration. Acta Oncol 2011;50:1183-90. [PMID: 21495791 DOI: 10.3109/0284186X.2011.572912] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
301 Lin SH. The utility of proton beam therapy with concurrent chemotherapy for the treatment of esophageal cancers. Cancers (Basel) 2011;3:4090-101. [PMID: 24213126 DOI: 10.3390/cancers3044090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466. [PMID: 22035459 DOI: 10.1186/1471-2407-11-466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
303 Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2011;30:94. [PMID: 21970688 DOI: 10.1186/1756-9966-30-94] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
304 Michel P, Di Fiore F. [Chemotherapy and rectal cancer]. Cancer Radiother 2011;15:436-9. [PMID: 21885319 DOI: 10.1016/j.canrad.2011.06.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
306 Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, Gong Y, Shao C. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One 2011;6:e23427. [PMID: 21858113 DOI: 10.1371/journal.pone.0023427] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
307 Guo W, Jiang YG. Current gene expression studies in esophageal carcinoma. Curr Genomics 2009;10:534-9. [PMID: 20514215 DOI: 10.2174/138920209789503888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
308 Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, Yaremko B, Younus J, Sanatani M, Vincent M, Dingle B, Fortin D, Inculet R. What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer? Curr Oncol 2010;17:46-51. [PMID: 21151409 DOI: 10.3747/co.v17i6.561] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
309 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
310 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
311 Ishihara R, Yamamoto S, Iishi H, Nagai K, Matui F, Kawada N, Ohta T, Kanzaki H, Hanafusa M, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Sugimoto N, Kawaguchi Y, Nishiyama K, Motoori M, Yano M, Hosoki T. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 2012;17:225-32. [PMID: 21735356 DOI: 10.1007/s10147-011-0278-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
312 Wahba HA, El-Hadaad HA, Abd-Ellatif EA. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Med Oncol 2012;29:1693-8. [PMID: 21706368 DOI: 10.1007/s12032-011-0001-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
313 McGrath EE, Warriner D, Anderson P. Is there a beneficial role for a flexible bronchoscopic approach to oesophageal tumour-related tracheobronchial stenosis? Lung 2011;189:401-7. [PMID: 21688114 DOI: 10.1007/s00408-011-9309-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
314 Yu E, Tai P, Younus J, Malthaner R, Truong P, Stitt L, Rodrigues G, Ash R, Dar R, Yaremko B, Tomiak A, Dingle B, Sanatani M, Vincent M, Kocha W, Fortin D, Inculet R. Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience. Curr Oncol 2009;16:48-54. [PMID: 19672424 DOI: 10.3747/co.v16i4.355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
315 Hsieh CH, Liu CY, Hsieh YJ, Tai HC, Wang LY, Tsai TH, Chen YJ. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil. PLoS One 2011;6:e21000. [PMID: 21695264 DOI: 10.1371/journal.pone.0021000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
316 Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55. [PMID: 21615894 DOI: 10.1186/1748-717x-6-55] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
317 Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011;11:176. [PMID: 21586140 DOI: 10.1186/1471-2407-11-176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
318 Tabuchi S, Ozawa S, Koyanagi K, Shigematsu N, Kubo A, Ueda M, Kitagawa Y, Kitajima M. Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines. Exp Ther Med 2011;2:601-6. [PMID: 22977547 DOI: 10.3892/etm.2011.263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
319 Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012;82:1967-72. [PMID: 21507583 DOI: 10.1016/j.ijrobp.2011.01.043] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
320 Gao MC, Jia XD, Wu QF, Cheng Y, Chen FR, Zhang J. Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation. Acta Pharmacol Sin 2011;32:528-36. [PMID: 21468086 DOI: 10.1038/aps.2010.235] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
321 Booth CM, Ohorodnyk P, Zhu L, Tu D, Meyer RM. Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation. Eur J Cancer 2011;47:854-63. [PMID: 21296570 DOI: 10.1016/j.ejca.2010.12.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
322 Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 2011;68:863-70. [PMID: 21286719 DOI: 10.1007/s00280-011-1556-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
323 Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2011;104:265-71. [PMID: 21157450 DOI: 10.1038/sj.bjc.6606051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
324 Forquer JA. Thymic neoplasms. Curr Probl Cancer 2010;34:328-66. [PMID: 21112444 DOI: 10.1016/j.currproblcancer.2010.10.001] [Reference Citation Analysis]
325 Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, Michel P. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510. [PMID: 20868479 DOI: 10.1186/1471-2407-10-510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
326 Ruiz-Cabello J, Barnett BP, Bottomley PA, Bulte JW. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed 2011;24:114-29. [PMID: 20842758 DOI: 10.1002/nbm.1570] [Cited by in Crossref: 326] [Cited by in F6Publishing: 320] [Article Influence: 27.2] [Reference Citation Analysis]
327 Kawazoe K, Isomoto H, Yamaguchi N, Inoue N, Uehara R, Matsushima K, Ichikawa T, Takeshima F, Nonaka T, Nanashima A, Nagayasu T, Uehara M, Asahina I, Nakao K. Effects of photodynamic therapy for superficial esophageal squamous cell carcinoma in vivo and in vitro. Oncol Lett 2010;1:877-82. [PMID: 22966398 DOI: 10.3892/ol_00000155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
328 Wijnhoven BP, van Lanschot JJ, Tilanus HW, Steyerberg EW, van der Gaast A. Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg 2009;33:2606-14. [PMID: 19760309 DOI: 10.1007/s00268-009-0223-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
329 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
330 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
331 Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713-8. [PMID: 20354452 DOI: 10.1097/JTO.0b013e3181d7776d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
332 Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol. 2010;186:374-381. [PMID: 20582393 DOI: 10.1007/s00066-010-2137-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
333 Kobayashi D, Koike M, Kodera Y, Fujiwara M, Nakayama G, Nakao A. Carcinosarcoma of the esophagus treated with chemoradiotherapy: report of four cases. Esophagus 2010;7:119-25. [DOI: 10.1007/s10388-010-0233-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
334 Amdal CD, Jacobsen AB, Tausjø JE, Wiig JN, Warloe T, Karlsen KO, Sandstad B, Bjordal K. Radical treatment for oesophageal cancer patients unfit for surgery and chemotherapy. A 10-year experience from the Norwegian Radium Hospital. Acta Oncol 2010;49:209-18. [PMID: 19929566 DOI: 10.3109/02841860903246573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
335 Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci 2010;55:3304-14. [PMID: 20300841 DOI: 10.1007/s10620-010-1187-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
336 Forastiere AA. Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus 2010;7:1-6. [DOI: 10.1007/s10388-009-0226-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
337 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 2010;7:48-54. [PMID: 20151048 DOI: 10.7150/ijms.7.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
338 Cohen RJ, Paskalev K, Litwin S, Price RA Jr, Feigenberg SJ, Konski AA. Esophageal motion during radiotherapy: quantification and margin implications. Dis Esophagus 2010;23:473-9. [PMID: 20095993 DOI: 10.1111/j.1442-2050.2009.01037.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
339 Tong DK, Law S. Management of oesophageal cancer. Indian J Surg 2009;71:317-25. [PMID: 23133184 DOI: 10.1007/s12262-009-0087-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
340 Park JC, Lee YC, Kim SK, Kim YJ, Shin SK, Lee SK, Kim H, Kim CB. Achalasia combined with esophageal cancer treated by concurrent chemoradiation therapy. Gut Liver 2009;3:329-33. [PMID: 20431771 DOI: 10.5009/gnl.2009.3.4.329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Trivin F, Boucher E, Vauléon E, Cumin I, Le Prisé E, Audrain O, Raoul JL. Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis. J Oncol 2009;2009:173421. [PMID: 20069042 DOI: 10.1155/2009/173421] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
342 Abrams JA, Buono DL, Strauss J, McBride RB, Hershman DL, Neugut AI. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115:4924-4933. [PMID: 19637343 DOI: 10.1002/cncr.24536] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
343 Cheng S, Iannettoni M, Koshy M, Suntharalingam M, Urba S. Squamous cell carcinoma of the esophagus: treat with how many modalities? Semin Oncol 2009;36:493-7. [PMID: 19995639 DOI: 10.1053/j.seminoncol.2009.09.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
344 Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer 2009;9:408. [PMID: 19930599 DOI: 10.1186/1471-2407-9-408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
345 Wilson KS, Barnett JB, Shah A, Khoo KE. The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer. Curr Oncol 2009;16:9-14. [PMID: 19862357 DOI: 10.3747/co.v16i5.369] [Reference Citation Analysis]
346 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009;6:305-11. [PMID: 19834547 DOI: 10.7150/ijms.6.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
347 Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009;75:489-96. [PMID: 19735873 DOI: 10.1016/j.ijrobp.2009.06.014] [Cited by in Crossref: 172] [Cited by in F6Publishing: 144] [Article Influence: 13.2] [Reference Citation Analysis]
348 Zuiki T, Hosoya Y, Ui T, Haruta H, Kurashina K, Saito S, Lefor A, Niki T, Nakazawa M, Yasuda Y. Therapeutic effectiveness of chemoradiotherapy for carcinosarcoma of the esophagus: two case reports and a review of the literature. Esophagus 2009;6:189-95. [DOI: 10.1007/s10388-009-0187-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
349 Jensen AD, Grehn C, Nikoghosyan A, Thieke C, Krempien R, Huber PE, Debus J, Münter MW. Catch me if you can--the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol. 2009;185:469-473. [PMID: 19714309 DOI: 10.1007/s00066-009-1935-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
350 Kurokawa Y, Muto M, Minashi K, Boku N, Fukuda H; Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group (JCOG). A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. Jpn J Clin Oncol. 2009;39:686-689. [PMID: 19703839 DOI: 10.1093/jjco/hyp078] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
351 Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S. Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol 2006;45:1120-5. [PMID: 17118849 DOI: 10.1080/02841860600609768] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
352 Cwikiel M, Cwikiel W, Albertsson M. Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. Acta Oncol 1996;35:75-9. [PMID: 8619944 DOI: 10.3109/02841869609098483] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
353 Fagerberg J, Stockeld D, Lewensohn R. Combined treatment modalities in esophageal cancer. Should chemotherapy be included? Acta Oncol 1994;33:439-50. [PMID: 8018378 DOI: 10.3109/02841869409098441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
354 Stockeld D, Backman L, Fagerberg J, Granström L. Esophageal cancer in Stockholm county 1978-1995. Acta Oncol 2007;46:1075-84. [PMID: 17851831 DOI: 10.1080/02841860701426807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
355 Cwikiel M, Albertsson M, Hambraeus G. Acute and delayed effects of radiotherapy in patients with oesophageal squamous cell carcinoma treated with chemotherapy, surgery and pre- and postoperative radiotherapy. Acta Oncol 1994;33:49-53. [PMID: 8142124 DOI: 10.3109/02841869409098375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
356 Servagi-Vernat S, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Maingon P, Mercier M, Bosset JF. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study. Drugs Aging 2009;26:255-62. [PMID: 19358620 DOI: 10.2165/00002512-200926030-00006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
357 Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61:388-401. [PMID: 19135108 DOI: 10.1016/j.addr.2008.10.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
358 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
359 Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci 2009;24:120-5. [PMID: 19270824 DOI: 10.3346/jkms.2009.24.1.120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
360 Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol 2009;27:1712-21. [PMID: 19237631 DOI: 10.1200/JCO.2008.19.5339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
361 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8. [PMID: 19214447 DOI: 10.1007/s11748-008-0337-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
362 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
363 van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8:21. [PMID: 19036143 DOI: 10.1186/1471-2482-8-21] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
364 Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, Paillot B, Michel P. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008;99:1586-92. [PMID: 19002180 DOI: 10.1038/sj.bjc.6604749] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
365 Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of esophageal cancer patients treated with radical intent. Can J Gastroenterol 2008;22:393-8. [PMID: 18414715 DOI: 10.1155/2008/231878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
366 Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 2008;99:1020-6. [PMID: 18797462 DOI: 10.1038/sj.bjc.6604659] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
367 Lecleire S, Di Fiore F, Antonietti M, Ben-Soussan E, Hochain P, Lerebours E, Michel P, Ducrotté P. Nonoperable patients with superficial esophageal cancer treated by photodynamic therapy after chemoradiotherapy have more severe complications than patients treated in primary intent. Am J Gastroenterol 2008;103:2215-9. [PMID: 18844614 DOI: 10.1111/j.1572-0241.2008.02042.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
368 Paganin F, Schouler L, Cuissard L, Noel JB, Becquart JP, Besnard M, Verdier L, Rousseau D, Arvin-Berod C, Bourdin A. Airway and esophageal stenting in patients with advanced esophageal cancer and pulmonary involvement. PLoS One 2008;3:e3101. [PMID: 18769726 DOI: 10.1371/journal.pone.0003101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
369 Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14(20): 3165-3173 [PMID: 18506920 DOI: 10.3748/wjg.14.3165] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
370 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. [PMID: 18309943 DOI: 10.1200/JCO.2007.12.9593] [Cited by in Crossref: 860] [Cited by in F6Publishing: 372] [Article Influence: 61.4] [Reference Citation Analysis]
371 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Cáncer de esófago. Medicina Clínica 2008;130:423-8. [DOI: 10.1157/13117853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
372 Corn BW, Wexler ID, Suntharalingam M, Inbar M, Curran WJ Jr; Radiation Therapy Oncology Group. Globalization of the Radiation Therapy Oncology Group: implementation of a model for service expansion and public health improvement. J Clin Oncol 2008;26:1160-6. [PMID: 18309952 DOI: 10.1200/JCO.2007.14.3891] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
373 Saito H, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Tsuyuguchi T, Kimura F. Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:63-68. [PMID: 18274845 DOI: 10.1007/s00534-007-1281-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
374 Kogo M, Suzuki A, Kaneko K, Yoneyama K, Imawari M, Kiuchi Y. Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer. Dig Dis Sci 2008;53:2415-21. [PMID: 18256935 DOI: 10.1007/s10620-007-0149-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
375 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
376 Nishimura M, Daiko H, Yoshida J, Nagai K. Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2007;55:461-4; discussion 464-5. [PMID: 18049854 DOI: 10.1007/s11748-007-0157-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
377 Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63. [PMID: 17680847 DOI: 10.1111/j.1572-0241.2007.01437.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 7.7] [Reference Citation Analysis]
378 López Carrizosa MC, Samper Ots PM, Rodríguez Pérez A, Sotoca A, Sáez Garrido J, de Miguel MM. High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED). Clin Transl Oncol 2007;9:385-91. [DOI: 10.1007/s12094-007-0071-y] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
379 Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96:1823-1827. [PMID: 17533399 DOI: 10.1038/sj.bjc.6603821] [Cited by in Crossref: 43] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
380 Djulbegovic B, Hozo I. When should potentially false research findings be considered acceptable? PLoS Med 2007;4:e26. [PMID: 17326703 DOI: 10.1371/journal.pmed.0040026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
381 Fukumitsu N, Tokuuye K, Sugahara S, Hashimoto T, Hata M, Ohara K, Shibahara T, Nakahara A, Akine Y. A patient surviving for eight years after proton and x-ray irradiation for advanced esophageal cancer. Acta Oncol 2006;45:1132-4. [PMID: 17118851 DOI: 10.1080/02841860600681577] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
382 Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006;11:454-60. [PMID: 17180514 DOI: 10.1007/s10147-006-0610-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
383 Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95:705-709. [PMID: 16967056 DOI: 10.1038/sj.bjc.6603328] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
384 Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006;41:425-32. [PMID: 16799883 DOI: 10.1007/s00535-006-1771-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
385 Hyodo I. Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol 2006;41:504-6. [PMID: 16799897 DOI: 10.1007/s00535-006-1835-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
386 Law S, Wong J. Esophageal cancer. Curr Opin Gastroenterol 2000;16:386-91. [PMID: 17031106 DOI: 10.1097/00001574-200007000-00016] [Reference Citation Analysis]
387 Blom D, Peters JH. Surgery, radiotherapy, and chemotherapy in carcinoma of the esophagus. Curr Opin Gastroenterol 2000;16:392-9. [PMID: 17031107 DOI: 10.1097/00001574-200007000-00017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Vats HS, Banerjee TK, Resnick J, Khan Q. Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy. Clin Med Res 2006;4:184-8. [PMID: 16988098 DOI: 10.3121/cmr.4.3.184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
389 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
390 Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478. [PMID: 16552197 DOI: 10.1097/01.sla.0000208430.07050.61] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 7.8] [Reference Citation Analysis]
391 Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692. [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b] [Cited by in Crossref: 256] [Cited by in F6Publishing: 242] [Article Influence: 15.1] [Reference Citation Analysis]
392 Hagenmüller F. [Palliative options for esophageal carcinoma]. Chirurg 2005;76:1044-52. [PMID: 16252084 DOI: 10.1007/s00104-005-1111-1] [Reference Citation Analysis]
393 Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J Gastroenterol 2005; 11(36): 5696-5700 [PMID: 16237768 DOI: 10.3748/wjg.v11.i36.5696] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
394 Liu HC, Hung SK, Huang CJ, Chen CC, Chen MJ, Chang CC, Tai CJ, Tzen CY, Lu LH, Chen YJ. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11(34): 5367-5372 [PMID: 16149148 DOI: 10.3748/wjg.v11.i34.5367] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
395 Korn WM. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004;5:405-416. [PMID: 15341678 DOI: 10.1007/s11864-004-0030-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
396 Nathanson DR, Thomas CR Jr, Bleday R. Recent clinical trials summary. Surg Oncol Clin N Am 2004;13:389-94. [PMID: 15137964 DOI: 10.1016/j.soc.2003.12.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
397 Walther B, Johansson J, Johnsson F, Von Holstein CS, Zilling T. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg. 2003;238:803-812; discussion 812-814. [PMID: 14631217 DOI: 10.1097/01.sla.0000098624.04100.b1] [Cited by in Crossref: 156] [Cited by in F6Publishing: 133] [Article Influence: 8.2] [Reference Citation Analysis]
398 Kelly MD, Walsh TN. Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ J Surg 2003;73:976-8. [PMID: 14632885 DOI: 10.1046/j.1445-2197.2003.t01-20-.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
399 Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003;89:630-3. [PMID: 12915869 DOI: 10.1038/sj.bjc.6601168] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
400 Macdonald JS. Advances in the therapy of gastric cancer. Gastric Cancer 2002;5 Suppl 1:35-40. [PMID: 12772886 DOI: 10.1007/s10120-002-0205-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
401 Chirat E. La curiethérapie endo-œsophagienne. Cancer/Radiothérapie 2003;7:132-5. [DOI: 10.1016/s1278-3218(03)00004-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
402 Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24. [PMID: 12556953 DOI: 10.1038/sj.bjc.6600684] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 3.4] [Reference Citation Analysis]
403 Allum WH, Griffin SM, Watson A, Colin-Jones D; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland., British Society of Gastroenterology., British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50 Suppl 5:v1-23. [PMID: 12049068 DOI: 10.1136/gut.50.90005.v1] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
404 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
405 Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002;86:669-673. [PMID: 11875723 DOI: 10.1038/sj.bjc.6600166] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 2.8] [Reference Citation Analysis]
406 Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer. Am J Gastroenterol 2002;97:452-8. [PMID: 11866287 DOI: 10.1111/j.1572-0241.2002.05499.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
407 Symonds RP. Recent advances: Radiotherapy. BMJ 2001;323:1107-10. [PMID: 11701579 DOI: 10.1136/bmj.323.7321.1107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
408 Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234:581-7. [PMID: 11685019 DOI: 10.1097/00000658-200111000-00001] [Cited by in Crossref: 156] [Cited by in F6Publishing: 133] [Article Influence: 7.4] [Reference Citation Analysis]
409 Maingon P, Manfredi S. Adénocarcinome du bas œsophage et du cardia: prise en charge non chirurgicale. Cancer/Radiothérapie 2001;5:98s-106s. [DOI: 10.1016/s1278-3218(01)80014-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
410 Seitz J, Duffaud F, Dahan L, Ries P, Ville E, Laugier R. Adénocarcinomes du bas œsophage et du cardia: quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases? Cancer/Radiothérapie 2001;5:107s-12s. [DOI: 10.1016/s1278-3218(01)80015-9] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
411 George CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L, Vokes EE. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001;19:303-10. [PMID: 11561689 DOI: 10.1023/a:1010653508700] [Cited by in Crossref: 14] [Article Influence: 0.7] [Reference Citation Analysis]
412 Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J, Glineur D, Romagnoli R, Reynaert M, Kestens PJ. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32. [PMID: 11420480 DOI: 10.1097/00000658-200107000-00005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
413 Vakil N, Morris AI, Marcon N, Segalin A, Peracchia A, Bethge N, Zuccaro G, Bosco JJ, Jones WF. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96:1791-6. [PMID: 11419831 DOI: 10.1111/j.1572-0241.2001.03923.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 161] [Article Influence: 9.7] [Reference Citation Analysis]
414 Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299-313. [PMID: 11081567 DOI: 10.1023/a:1006416410198] [Cited by in Crossref: 237] [Cited by in F6Publishing: 81] [Article Influence: 10.8] [Reference Citation Analysis]
415 Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 2000;95:2086-93. [PMID: 10950062 DOI: 10.1111/j.1572-0241.2000.02173.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 3.4] [Reference Citation Analysis]
416 Thorban S, Rosenberg R, Busch R, Roder RJ. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. Br J Cancer 2000;83:35-9. [PMID: 10883665 DOI: 10.1054/bjoc.2000.1199] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 1.7] [Reference Citation Analysis]
417 Thomas AL, O'Byrne K, Steward WP. Chemotherapy for upper gastrointestinal tumours. Postgrad Med J 2000;76:321-7. [PMID: 10824043 DOI: 10.1136/pmj.76.896.321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
418 Abrams RA. Is there a Role for Radiotherapy in the Management of Upper Gastrointestinal Malignancies? Surgical Oncology Clinics of North America 2000;9:525-38. [DOI: 10.1016/s1055-3207(18)30138-8] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
419 Lord RV. Optimal treatment for localized esophageal cancer still uncertain. Am J Gastroenterol 2000;95:305-7. [PMID: 10638607 DOI: 10.1111/j.1572-0241.2000.01738.x] [Reference Citation Analysis]
420 van der Gaast A, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TA. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 1999;80:1052-7. [PMID: 10362115 DOI: 10.1038/sj.bjc.6690462] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
421 Yamanaka H, Motohiro T, Michiura T, Asai A, Mori T, Hioki K. Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Jpn J Thorac Cardiovasc Surg 1998;46:943-8. [PMID: 9847566 DOI: 10.1007/BF03217851] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
422 Calais G. [Concomitant chemoradiotherapy of cancer of the esophagus]. Cancer Radiother 1998;2:689-95. [PMID: 9922774 DOI: 10.1016/s1278-3218(99)80009-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
423 Mukai M, Morita S. Phase II study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Int J Clin Oncol 1998;3:370-3. [DOI: 10.1007/bf00539215] [Reference Citation Analysis]
424 Anand BS, Saeed ZA, Michaletz PA, Winchester CB, Doherty MA, Liem JH, Graham DY. A randomized comparison of dilatation alone versus dilatation plus laser in patients receiving chemotherapy and external beam radiation for esophageal carcinoma. Dig Dis Sci 1998;43:2255-60. [PMID: 9790462 DOI: 10.1023/a:1026618706464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
425 Price P, Hoskin PJ, Hutchinson T, Stenning S. What is the role of radiation-chemotherapy in the radical non-surgical management of carcinoma of the oesophagus? Upper GI Cancer Working Party of the UK Medical Research Council. Br J Cancer 1998;78:504-7. [PMID: 9716034 DOI: 10.1038/bjc.1998.522] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
426 Takamura A, Ohara M, Hosokawa M, Nishino S, Shirato H, Saito H. Combined chemotherapy with twice-daily radiation therapy for inoperable squamous cell carcinoma of the thoracic esophagus. Int J Clin Oncol 1997;2:189-96. [DOI: 10.1007/bf02488990] [Reference Citation Analysis]
427 Stuschke M, Sauer R. [Multimodal therapy or surgery alone in adenocarcinoma of the esophagus?]. Strahlenther Onkol 1997;173:486-7. [PMID: 9340841 DOI: 10.1007/BF03038190] [Reference Citation Analysis]
428 Fritz P, Wannenmacher M. Radiotherapy in the multimodal treatment of esophageal carcinoma. Strahlenther Onkol. 1997;173:295-308. [PMID: 9235637 DOI: 10.1007/BF03038912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
429 Choy H. Combining radiation and chemotherapy: Current status and future directions. Seminars in Radiation Oncology 1997;7:1-3. [DOI: 10.1016/s1053-4296(97)80053-7] [Reference Citation Analysis]
430 Slabber CF, Falkson G, Burger W, Schoeman L. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: A phase II trial. Invest New Drugs. 1996;14:391-394. [PMID: 9157075 DOI: 10.1007/bf00180816] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
431 Lichtman SM, Bayer R. Gastrointestinal Cancer in the Elderly. Clinics in Geriatric Medicine 1997;13:307-26. [DOI: 10.1016/s0749-0690(18)30171-x] [Reference Citation Analysis]
432 Ball D, Smith J, Bishop J, Olver I, Davis S, O'Brien P, Bernshaw D, Ryan G, Millward M. A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer. Br J Cancer 1997;75:690-7. [PMID: 9043026 DOI: 10.1038/bjc.1997.123] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 1.6] [Reference Citation Analysis]
433 Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer. 1996;74:1651-1654. [PMID: 8932350 DOI: 10.1038/bjc.1996.604] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.3] [Reference Citation Analysis]
434 Taal BG, Aleman BM, Koning CC, Boot H. High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer. Br J Cancer 1996;74:1452-7. [PMID: 8912544 DOI: 10.1038/bjc.1996.564] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
435 Wong WW, Schild SE, Martenson JA. Role of Radiation Therapy and Fluoropyrimidines in the Treatment of Gastrointestinal Malignancies. Cancer Control 1996;3:319-28. [PMID: 10765223 DOI: 10.1177/107327489600300403] [Reference Citation Analysis]
436 Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996;223:127-133. [PMID: 8597505 DOI: 10.1097/00000658-199602000-00003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 80] [Article Influence: 3.9] [Reference Citation Analysis]
437 Kato H. Diagnosis and treatment of esophageal neoplasms. Jpn J Cancer Res 1995;86:993-1009. [PMID: 8567405 DOI: 10.1111/j.1349-7006.1995.tb03012.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
438 Verschakelen JA, de Leyn P, Bogaert J, Baert AL. Oncology imaging: nodal spread-intrathoracic nodes. Eur Radiol 1996;6:251-61. [PMID: 8797994 DOI: 10.1007/BF00180590] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
439 Raoul JL, Le Prisé E, Meunier B, Julienne V, Etienne PL, Gosselin M, Launois B. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 1995;37:174-6. [PMID: 7557562 DOI: 10.1136/gut.37.2.174] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
440 Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685-93; discussion 693-5. [PMID: 7794073 DOI: 10.1097/00000658-199506000-00008] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 3.4] [Reference Citation Analysis]
441 Bamias A, Cunningham D, Nicolson V, Norman A, Hill M, Nicolson M, O'Brien M, Webb A, Hill A. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Br J Cancer 1995;71:583-6. [PMID: 7880742 DOI: 10.1038/bjc.1995.113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
442 Cunningham D. Important progress in treatment. Chemotherapy for solid tumours. BMJ 1995;310:247-8. [PMID: 7866134 DOI: 10.1136/bmj.310.6974.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
443 Sauter ER, Coia LR, Keller SM. Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction. Ann Surg Oncol 1994;1:5-10. [PMID: 7834428 DOI: 10.1007/BF02303535] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
444 O'Reilly S, Forastiere A. New approaches to treating oesophageal cancer. BMJ 1994;308:1249-50. [PMID: 8205011 DOI: 10.1136/bmj.308.6939.1249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
445 Ellis P, Cunningham D. Management of carcinomas of the upper gastrointestinal tract. BMJ 1994;308:834-8. [PMID: 8167493 DOI: 10.1136/bmj.308.6932.834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
446 Greager JA, Donahue PE, Reichard K, Kucich V, Lubienski M, Barker W, Reyes HM. Endoscopically defined treatment strategies in patients with locally advanced esophageal cancer. Surg Endosc 1994;8:384-7; discussion 387-8. [PMID: 8073353 DOI: 10.1007/BF00642437] [Reference Citation Analysis]
447 Millar J. Surgery for oesophageal squamous cell carcinoma. Lancet 1994;343:1099. [PMID: 7909114 DOI: 10.1016/s0140-6736(94)90209-7] [Reference Citation Analysis]
448 Schwartz GK. c-sis and oncogene expression: a fundamental approach toward understanding esophageal cancer. Cancer Invest 1994;12:266-7. [PMID: 8131104 DOI: 10.3109/07357909409024885] [Reference Citation Analysis]
449 Spielmann M, Gandia D, Fizazi K, Guillot T, Cvitkovic E, Kayitalire L, Girinsky T, Elias D, Rougier P, Kac J. Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer. Eur J Cancer 1994;30A:1908-9. [PMID: 7880628 DOI: 10.1016/0959-8049(94)00254-3] [Reference Citation Analysis]